- New serotonin 5-HT1A receptor agonists with neuroprotective effect against ischemic cell damage
-
We report the synthesis of new compounds 4-35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT1A receptor (5-HT1AR). Computational β2-based homology models of the ligand-receptor complexes were used to explain the observed structure-affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4-dihydro-2H- chromen-2-ylmethyl)amino]hexyl}tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H) -dione) has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 5.9 nM, EC50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.
- Marco, Isabel,Valhondo, Margarita,Martín-Fontecha, Mar,Vázquez-Villa, Henar,Del Río, Joaquín,Planas, Anna,Sagredo, Onintza,Ramos, José A.,Torrecillas, Iván R.,Pardo, Leonardo,Frechilla, Diana,Benhamú, Bellinda,López-Rodríguez, María L.
-
p. 7986 - 7999
(2012/01/13)
-
- Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
-
This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.
- -
-
-